Used in gene therapy, the CD34+ PBMCs (lymphoid and myeloid progenitors) transduced with normal ABCD1 can efficiently correct the clinical phenotype of the X-ALD patients [82]. This evidence concerns the gene ABCD1 and X-linked adrenoleukodystrophy.